ReviewCancer management and research2025
Advances in Cancer Vaccines for Digestive System Cancers: A Systematic Analysis of Clinical Trials.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07510308 (A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of MSH2-/- Tumor Cell Vaccines in Patients With Advanced pMMR Colorectal Cancer.), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of MSH2-/- Tumor Cell Vaccines in Patients With Advanced pMMR Colorectal Cancer.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Digestive system cancers, including gastric, liver, pancreatic, and colorectal cancers, are the leading causes of cancer-related deaths worldwide. Conventional treatments, such as surgery and chemotherapy, have limited efficacy in the treatment of advanced digestive system cancers, necessitating the development of new and effective therapeutic strategies. This study review aimed to evaluate the potential of cancer vaccines in the treatment of digestive system cancers and explore the prospects for the clinical application of different vaccine types. Methods: We analyzed data from clinical trials of cancer vaccines related to cancers of the digestive system. The screening criteria included data on the trial design, therapeutic targets, efficacy, and safety. Results: A total of 165 clinical trials that met the inclusion criteria were screened, mainly investigating nucleic acid and peptide vaccines, with the largest number of vaccine studies targeting colorectal and pancreatic cancers. Trial results demonstrated that cancer vaccines have the potential to treat cancers of the digestive system, with the particular advantages of enhancing immune responses and reducing tumor resistance. Conclusion: Cancer vaccines, particularly nucleic acid and peptide vaccines, demonstrate potential as therapeutic interventions for digestive system cancers. Nucleic acid vaccines offer advantages in scalability and rapid design; however, they face limitations in delivery efficiency and immune activation. In contrast, peptide vaccines are safer and more stable than nucleic acid ones; however, they often elicit comparatively weaker immune responses. Therefore, it is essential to address platform-specific challenges. Future clinical trials should be strategically designed to evaluate and optimize these distinct platforms to accelerate their translation to clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.